tirzepatide cardiovascular outcomes Long-awaited SURPASS-CVOT: with vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function Possible mechanisms of Tirzepatide's cardiovascular

Mirroring the case of tirzepatide, the FDA in February formally ended the shortage for Novos semaglutide, which also met with an OFA lawsuit that Novo later joined

In the new study, Rodriguez and colleagues analyzed electronic health records from more than 41,000 adults who were overweight or had obesity and had been prescribed one of the two drugs for the first time

The 30-unit syringe (0.3ml), the 50-unit syringe (0.5ml), and the 100-unit syringe (1ml)

Sergey Terushkin, MD, FACS The medication helps control hunger, but long-term success usually comes from combining treatment with healthy habits

Monitor your levels closely and speak with your provider about lowering doses of those drugs if needed

There is no perfect medication for obesity